Last reviewed · How we verify
Gaviscon (ALGELDRATE)
Gaviscon (generic name: ALGELDRATE) is a algeldrate Small molecule drug developed by Sanofi. It is currently FDA-approved (first approved 1983) for Duodenal ulcer disease, Gastric Hypersecretory Conditions, Gastric ulcer.
At a glance
| Generic name | ALGELDRATE |
|---|---|
| Sponsor | Sanofi |
| Drug class | algeldrate |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
| First approval | 1983 |
Approved indications
- Duodenal ulcer disease
- Gastric Hypersecretory Conditions
- Gastric ulcer
- Gastroesophageal reflux disease
- Heartburn
- Indigestion
- Peptic ulcer
Common side effects
Drug interactions
- cefdinir
- cefpodoxime proxetil
- ciprofloxacin
- doxycycline
- eltrombopag
- enoxacin
- ethambutol
- gatifloxacin
- itraconazole
- ketoconazole
- levothyroxine sodium
- lomefloxacin
Key clinical trials
- Safety and Immunogenicity of an Inactivated West Nile Virus Vaccine in Healthy Adults (PHASE1)
- A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes (PHASE1)
- A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children. (PHASE3)
- Alginate vs Sucralfate for GERD Symptomatic Relief (PHASE2,PHASE3)
- A First in Human Trial to Assess the Safety and Immunogenicity of LTB-SA7 Vaccine Against Staphylococcus Aureus. (PHASE1)
- An Efficacy, Safety, and Immunogenicity Study of CHIKV VLP Vaccine for the Prevention of Chikungunya Disease in Adolescents and Adults (PHASE3)
- Safety and Efficacy of wSp Vaccine in Young Children (PHASE2)
- Efficacy of Na-GST-1/Alhydrogel Hookworm Vaccine Assessed by Controlled Challenge Infection (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gaviscon CI brief — competitive landscape report
- Gaviscon updates RSS · CI watch RSS
- Sanofi portfolio CI
Frequently asked questions about Gaviscon
What is Gaviscon?
Gaviscon (ALGELDRATE) is a algeldrate drug developed by Sanofi, indicated for Duodenal ulcer disease, Gastric Hypersecretory Conditions, Gastric ulcer.
What is Gaviscon used for?
Gaviscon is indicated for Duodenal ulcer disease, Gastric Hypersecretory Conditions, Gastric ulcer, Gastroesophageal reflux disease, Heartburn.
Who makes Gaviscon?
Gaviscon is developed and marketed by Sanofi (see full Sanofi pipeline at /company/sanofi).
What is the generic name of Gaviscon?
ALGELDRATE is the generic (nonproprietary) name of Gaviscon.
What drug class is Gaviscon in?
Gaviscon belongs to the algeldrate class. See all algeldrate drugs at /class/algeldrate.
When was Gaviscon approved?
Gaviscon was first approved on 1983.
What development phase is Gaviscon in?
Gaviscon is FDA-approved (marketed).
Related
- Drug class: All algeldrate drugs
- Manufacturer: Sanofi — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Duodenal ulcer disease
- Indication: Drugs for Gastric Hypersecretory Conditions
- Indication: Drugs for Gastric ulcer
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing